Reframing schizophrenia as a neurodevelopmental syndrome: The scientific and social imperative

That is the title of a paper published today with co-authors Arundati Nagendra (from the Schizophrenia and Psychosis Action Alliance), Raquelle Mesholam-Gately and Matcheri Keshavan (both at the Department of Psychiatry at Harvard Medical School). The abstract is here: Background Schizophrenia is traditionally classified as a serious mental illness (SMI), emphasizing chronicity and disability. However,…

Read More

Sutter, Allina Health Combine to Form $26B Health System

Sutter Health is acquiring Allina Health in a deal that would create a $26 billion nonprofit health system spanning California, Minnesota and Wisconsin. The deal reflects a broader wave of hospital consolidation as providers pursue scale to manage rising costs and fund tech investments. The post Sutter, Allina Health Combine to Form $26B Health System…

Read More

J&J Gets FDA Nod for Plaque Psoriasis Pill Positioned to Compete With Injectables

FDA approval of Icotyde covers the treatment of adults and adolescents with moderate-to-severe plaque psoriasis. This once-daily pill, developed by partners Johnson & Johnson and Protagonist Therapeutics, offers an easier dosing option compared to injectables and is projected to become a blockbuster seller across several immunological indications. The post J&J Gets FDA Nod for Plaque…

Read More

ChatGPT Health Exposes the Hard Truth About AI in Healthcare

The introduction of consumer-facing health AI should be understood less as a clinical breakthrough and more as a cultural one. Patients now expect their health information to be as accessible and navigable as their banking or travel data. That expectation will reshape how health systems design digital experiences and how vendors think about patient engagement….

Read More